Diabetes, Vol 43, Issue 2 173-179, Copyright © 1994 by American Diabetes Association

ARTICLES

Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats

JL Leahy, LM Bumbalo and C Chen
Endocrine Division, New England Medical Center, Boston, MA 02111.

Chronic hyperglycemia causes near-total disappearance of glucose-induced insulin secretion. The etiology has been suggested to be a nonsustainable stimulation of insulin release that causes beta-cells to become unresponsive to glucose through an undefined mechanism. We used an inhibitor of insulin secretion, diazoxide, to test this hypothesis in 90% pancreatectomized (Px) rats. Px rats were given 5 days of diazoxide (30 mg/kg orally twice a day) or tap water starting on postoperative day 8, 15, or 22. In vitro pancreas perfusions were conducted 36 h posttreatment (2, 3, or 4 weeks after surgery) using a protocol of 15 min of 16.7 mM glucose followed by 15 min of 16.7 mM glucose plus 10 mM arginine. In 2-week Px rats, insulin responses to 16.7 mM glucose and to glucose/arginine were both appropriate for the reduced beta-cell mass, i.e., no defect in beta-cell glucose responsiveness had yet occurred. Diazoxide had no affect on insulin release at this time. Between 2 and 3 weeks after pancreatectomy, insulin output to 16.7 mM glucose fell 75%, and that to glucose/arginine fell 50%. Diazoxide given at this time partially blocked the fall in glucose-induced insulin secretion and totally prevented that with arginine. The increased insulin secretion caused by diazoxide was accompanied by 1) lower nonfasting plasma glucose values, 2) improved glucose tolerance after oral glucose load, and 3) a 50% increase in pancreatic insulin content. Our results support the concept that excessive insulin secretion is a major cause of the hyperglycemia-induced loss of beta-cell glucose responsiveness. A leading candidate for the mechanism of this effect is depleted pancreatic insulin stores. Overstimulation of insulin secretion provides a new target for pharmacological therapy aimed at reducing glucose intolerance in non-insulin-dependent diabetes mellitus.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. L. Leahy Mary, Mary, Quite Contrary, How Do Your {beta}-Cells Fail? Diabetes, October 1, 2008; 57(10): 2563 - 2564. [Full Text] [PDF]

				B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF]

				J. Buteau, A. Shlien, S. Foisy, and D. Accili Metabolic Diapause in Pancreatic beta-Cells Expressing a Gain-of-function Mutant of the Forkhead Protein Foxo1 J. Biol. Chem., January 5, 2007; 282(1): 287 - 293. [Abstract] [Full Text] [PDF]

				M. Zdravkovic, M. Kruse, K. L. Rost, J. Moss, A. Kecskes, and T. Dyrberg The Effects of NN414, a SUR1/Kir6.2 Selective Potassium Channel Opener, in Healthy Male Subjects J. Clin. Pharmacol., July 1, 2005; 45(7): 763 - 772. [Abstract] [Full Text] [PDF]

				R. A. Ritzel, J. B. Hansen, J. D. Veldhuis, and P. C. Butler Induction of {beta}-Cell Rest by a Kir6.2/SUR1-Selective KATP-Channel Opener Preserves {beta}-Cell Insulin Stores and Insulin Secretion in Human Islets Cultured at High (11 mM) Glucose J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 795 - 805. [Abstract] [Full Text] [PDF]

				R. D. Carr, C. L. Brand, T. B. Bodvarsdottir, J. B. Hansen, and J. Sturis NN414, a SUR1/Kir6.2-Selective Potassium Channel Opener, Reduces Blood Glucose and Improves Glucose Tolerance in the VDF Zucker Rat Diabetes, October 1, 2003; 52(10): 2513 - 2518. [Abstract] [Full Text] [PDF]

				S. H. Song, C. J. Rhodes, J. D. Veldhuis, and P. C. Butler Diazoxide Attenuates Glucose-Induced Defects in First-Phase Insulin Release and Pulsatile Insulin Secretion in Human Islets Endocrinology, August 1, 2003; 144(8): 3399 - 3405. [Abstract] [Full Text] [PDF]

				M. Paris, C. Bernard-Kargar, M.-F. Berthault, L. Bouwens, and A. Ktorza Specific and Combined Effects of Insulin and Glucose on Functional Pancreatic {beta}-Cell Mass in Vivo in Adult Rats Endocrinology, June 1, 2003; 144(6): 2717 - 2727. [Abstract] [Full Text] [PDF]

				K. E. Cosgrove, M.-H. Antoine, A. T. Lee, P. D. Barnes, P. de Tullio, P. Clayton, R. McCloy, P. De Lonlay, C. Nihoul-Fekete, J.-J. Robert, et al. BPDZ 154 Activates Adenosine 5'-Triphosphate-Sensitive Potassium Channels: In Vitro Studies Using Rodent Insulin-Secreting Cells and Islets Isolated from Patients with Hyperinsulinism J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4860 - 4868. [Abstract] [Full Text] [PDF]

				S. Kooptiwut, S. Zraika, A. W. Thorburn, M. E. Dunlop, R. Darwiche, T. W. Kay, J. Proietto, and S. Andrikopoulos Comparison of Insulin Secretory Function in Two Mouse Models with Different Susceptibility to {beta}-Cell Failure Endocrinology, June 1, 2002; 143(6): 2085 - 2092. [Abstract] [Full Text] [PDF]

				V. Poitout and R. P. Robertson Minireview: Secondary {beta}-Cell Failure in Type 2 Diabetes--A Convergence of Glucotoxicity and Lipotoxicity Endocrinology, February 1, 2002; 143(2): 339 - 342. [Abstract] [Full Text] [PDF]

				T. Laedtke, L. Kjems, N. Porksen, O. Schmitz, J. Veldhuis, P. C. Kao, and P. C. Butler Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes Am J Physiol Endocrinol Metab, September 1, 2000; 279(3): E520 - E528. [Abstract] [Full Text] [PDF]

				J. L. Leahy and M. S. Fineman Impaired phasic insulin and amylin secretion in diabetic rats Am J Physiol Endocrinol Metab, September 1, 1998; 275(3): E457 - E462. [Abstract] [Full Text] [PDF]